12:00 AM
Nov 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

BioChain Institute, Epigenomics deal

BioChain and Epigenomics expanded a March deal granting BioChain Chinese rights to Epigenomics' septin 9 (SEPT9) biomarker to detect colorectal cancer (CRC) in blood. Under the expansion, Epigenomics said BioChain received an exclusive license to develop and commercialize the...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >